News

Pfizer Inc. (PFE): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential
We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...
Drug costs could skyrocket by $51 billion annually with proposed tariffs, report finds
The report, not made public, was commissioned by the main US pharmaceutical lobby, the Pharmaceutical Research and ...
Trump’s planned pharmaceutical tariffs would raise costs by $51bn annually, report finds
Prices of medication and other costs could increase by as much as 12.9 percent if the tariffs are put in place ...
Exclusive-US pharma tariffs would raise US drug costs by $51 billion annually, report finds
The analysis, conducted by Ernst & Young, found the United States imported $203 billion in pharmaceutical products in 2023, ...
Proposed pharma tariffs may spike US drug prices by 12.9%: EY report
Report warns 25% pharma tariff could add $51 billion to US drug costs, impacting prices and global competitiveness.
ZAWYA2d
US pharma tariffs would raise US drug costs by $51bln annually, report finds
The analysis, conducted by Ernst & Young, found the United States imported $203 billion in pharmaceutical products in 2023 ...
The Pharma Letter2d
Guardant Health and Pfizer team up
Precision oncology company Guardant Health has announced a strategic collaboration with Pfizer to support the development and ...
Zacks Investment Research on MSN2d
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
Pfizer's PFE non-COVID operational revenues improved in 2024, driven by its key in-line products like Vyndaqel, Padcev and ...
24/7 Wall St.3d
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...
Once all-powerful, pharma’s allies in Washington are fleeting
Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...